News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
174 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44432)
2016 (38329)
2017 (37187)
2018 (39119)
2019 (51334)
2020 (57662)
2021 (58720)
2022 (53927)
2023 (42564)
2024 (37440)
2025 (33091)
2026 (27455)
Month
January (2434)
February (2867)
March (3030)
April (3117)
May (3356)
June (2726)
July (2287)
August (2491)
September (2814)
October (2333)
Day
1 (26)
2 (174)
3 (177)
4 (143)
5 (222)
6 (34)
9 (203)
10 (138)
11 (95)
12 (124)
13 (105)
15 (21)
16 (103)
17 (104)
18 (170)
19 (133)
20 (75)
22 (7)
23 (133)
24 (158)
25 (111)
26 (117)
27 (109)
30 (214)
31 (134)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
August
September
October
Day
1
2
3
4
5
6
9
10
11
12
13
15
16
17
18
19
20
22
23
24
25
26
27
30
31
Regulatory
FDA Action Alert: BMS, GSK, Aldeyra and More
On the FDA’s docket this month are two decisions pushed back from 2025, including one for a rare form of obesity and another for dry eye disease.
March 2, 2026
·
4 min read
·
Tristan Manalac
Press Releases
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
March 2, 2026
·
19 min read
Press Releases
Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation
March 2, 2026
·
7 min read
Press Releases
PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
March 2, 2026
·
19 min read
Press Releases
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
March 2, 2026
·
19 min read
Press Releases
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025
March 2, 2026
·
20 min read
Press Releases
Median Technologies to present at the TD Cowen 46th Annual Health Care Conference
March 2, 2026
·
2 min read
Press Releases
Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
March 2, 2026
·
8 min read
Press Releases
ValGenesis to Showcase Process Lifecycle Suite at BioProcessing Summit Europe 2026
March 2, 2026
·
1 min read
Press Releases
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization
March 2, 2026
·
5 min read
1 of 18
Next
